| Dr Matthew J Nottingham, OD | |
|
534 North Last Chance Gulch, Helena, MT 59601 | |
| (406) 442-6814 | |
| (406) 443-7732 |
| Full Name | Dr Matthew J Nottingham |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 12 Years |
| Location | 534 North Last Chance Gulch, Helena, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316201874 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 1641 (Montana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Helena Vision Center Pc | 2860534989 | 2 |
News Archive
Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research.
Labopharm Inc. today announced it has settled the previously announced draw down of $1 million under its standby equity distribution (SEDA) with YA Global Master SPV Ltd. (YA). Under the draw down, Labopharm issued 482,165 of its common shares to YA at a price of $2.07 per common share, net of the applicable discount. (All currency figures are in Canadian dollars.)
Researchers have mapped in fine detail the genetic changes malaria parasites go through as they prepare to infect people.
This study suggests that genetically engineered malaria parasites that are stunted through precise gene deletions (genetically attenuated parasites, or "GAP") could be used as a vaccine that protects against malaria infection. This means that the harmless (attenuated) version of the parasite would interact with the body in the same way as the infective version, but without possibility of causing disease.
A new device that offers drug-free bedside filtered air flow can significantly reduce patients' symptoms such as wheezing and tight chests in asthmatics. The temperature controlled laminar airflow treatment, called Protexo, filters out airborne triggers such as dust particles and mites, pet hairs and powders that cause irritation and inflammation of the lungs.
› Verified 3 days ago
| Provider Name | Helena Vision Center Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1023231644 PECOS PAC ID: 2860534989 Enrollment ID: O20100127000471 |
News Archive
Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research.
Labopharm Inc. today announced it has settled the previously announced draw down of $1 million under its standby equity distribution (SEDA) with YA Global Master SPV Ltd. (YA). Under the draw down, Labopharm issued 482,165 of its common shares to YA at a price of $2.07 per common share, net of the applicable discount. (All currency figures are in Canadian dollars.)
Researchers have mapped in fine detail the genetic changes malaria parasites go through as they prepare to infect people.
This study suggests that genetically engineered malaria parasites that are stunted through precise gene deletions (genetically attenuated parasites, or "GAP") could be used as a vaccine that protects against malaria infection. This means that the harmless (attenuated) version of the parasite would interact with the body in the same way as the infective version, but without possibility of causing disease.
A new device that offers drug-free bedside filtered air flow can significantly reduce patients' symptoms such as wheezing and tight chests in asthmatics. The temperature controlled laminar airflow treatment, called Protexo, filters out airborne triggers such as dust particles and mites, pet hairs and powders that cause irritation and inflammation of the lungs.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Matthew J Nottingham, OD P.o. Box 844, Helena, MT 59624 Ph: (406) 442-6814 | Dr Matthew J Nottingham, OD 534 North Last Chance Gulch, Helena, MT 59601 Ph: (406) 442-6814 |
News Archive
Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research.
Labopharm Inc. today announced it has settled the previously announced draw down of $1 million under its standby equity distribution (SEDA) with YA Global Master SPV Ltd. (YA). Under the draw down, Labopharm issued 482,165 of its common shares to YA at a price of $2.07 per common share, net of the applicable discount. (All currency figures are in Canadian dollars.)
Researchers have mapped in fine detail the genetic changes malaria parasites go through as they prepare to infect people.
This study suggests that genetically engineered malaria parasites that are stunted through precise gene deletions (genetically attenuated parasites, or "GAP") could be used as a vaccine that protects against malaria infection. This means that the harmless (attenuated) version of the parasite would interact with the body in the same way as the infective version, but without possibility of causing disease.
A new device that offers drug-free bedside filtered air flow can significantly reduce patients' symptoms such as wheezing and tight chests in asthmatics. The temperature controlled laminar airflow treatment, called Protexo, filters out airborne triggers such as dust particles and mites, pet hairs and powders that cause irritation and inflammation of the lungs.
› Verified 3 days ago
Helena Vision Center, Pc Optometrist Medicare: Medicare Enrolled Practice Location: 534 N Last Chance Gulch St, Helena, MT 59601 Phone: 406-442-6814 Fax: 406-443-7732 | |
Standish Vision P.c Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2750 Prospect Ave, Helena, MT 59601 Phone: 406-495-8591 Fax: 406-495-8605 | |
Patricia M Hernacki, O.D. Optometrist Medicare: May Accept Medicare Assignments Practice Location: 301 Saddle Dr Ste B, Helena, MT 59601 Phone: 406-442-3937 Fax: 406-442-3366 | |
Marcus H Kelley, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 550 N Montana Ave, Helena, MT 59601 Phone: 406-443-2121 Fax: 406-443-4163 | |
Robert James Simons, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 550 N Montana Ave, Helena, MT 59601 Phone: 406-443-2121 Fax: 406-443-4163 | |
Dr. W. Bruce Coen, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 534 N Last Chance Gulch St, Helena, MT 59601 Phone: 406-442-6814 | |
Jesse Shane Standish, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2750 Prospect Ave, Helena, MT 59601 Phone: 406-495-8591 Fax: 406-495-8605 |